Revenue of $283.4 million in Q3, ahead of outlookDiluted EPS of $0.97 in Q3 and Adjusted Diluted EPS of $1.14, versus prior year Q3 Diluted EPS of $1.22Repurchased approximately 0.8 million shares opportunistically in Q3Successfully closed acquisition of eye care supplier Pillar5 Pharma, Inc. in December, as expectedNarrowing Outlook Range of Fiscal 2026 Revenue and Adjusted Diluted EPS TARRYTOWN, N.Y., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial r ...

Core Viewpoint - Prestige Consumer Healthcare Inc. is set to release its fiscal 2026 third quarter earnings on February 5, 2026, before market opening, followed by a conference call at 8:30 a.m. ET to discuss the results [1]. Group 1: Earnings Release and Conference Call - The earnings release for fiscal 2026 third quarter will be issued on February 5, 2026, before the market opens [1]. - A conference call to discuss the earnings results will take place on the same day at 8:30 a.m. ET [1]. - Participants can access the live Internet webcast from the Investor Relations page of the company's website [2]. Group 2: Conference Call Participation - Participants can register for the conference call to receive dial-in details and a unique pin, with a recommendation to join 10 minutes early [2]. - A replay of the conference call will be available for approximately one week following the live event [3]. Group 3: ICR Conference Participation - The company will participate in a fireside chat at the 28th Annual ICR Conference on January 13, 2026, at 9:30 a.m. ET [4]. - A live audio webcast of the ICR Conference event can be accessed from the Investor Relations page of the company's website [4]. - A replay of the webcast will be available later the same day [4]. Group 4: Company Overview - Prestige Consumer Healthcare is a leading consumer healthcare products company with sales in the U.S., Canada, Australia, and other international markets [5]. - The company's diverse portfolio includes brands such as Monistat®, Summer's Eve®, BC®, Goody's®, Clear Eyes®, TheraTears®, and many others [5].

Core Points - Prestige Consumer Healthcare Inc. will release its fiscal 2026 second quarter and first half earnings on November 6, 2025, before market opening [1] - A conference call to discuss the earnings results will take place on the same day at 8:30 a.m. ET [1] Company Overview - Prestige Consumer Healthcare Inc. markets, sells, manufactures, and distributes consumer healthcare products across the U.S., Canada, Australia, and other international markets [4] - The company's product portfolio includes brands such as Monistat®, Summer's Eve®, BC®, Goody's®, Clear Eyes®, TheraTears®, DenTek®, Dramamine®, Fleet®, Chloraseptic®, Luden's®, Compound W®, Little Remedies®, Boudreaux's Butt Paste®, Nix®, Debrox®, Gaviscon®, Hydralyte®, and Fess® [4]

Group 1 - Prestige Consumer Healthcare Inc. will present at the Barclays Global Consumer Staples Conference on September 4, 2025, at 12:45 p.m. ET [1] - Interested parties can access a live webcast of the event on the company's website under the "Investors" section [1] - A replay option will be available on the company's website for those unable to participate in the live webcast [1] Group 2 - Prestige Consumer Healthcare is a leading consumer healthcare products company with sales in the U.S., Canada, Australia, and other international markets [2] - The company's diverse portfolio includes brands such as Monistat®, Summer's Eve®, BC®, Goody's®, Clear Eyes®, TheraTears®, DenTek®, Dramamine®, Fleet®, Chloraseptic®, Luden's®, Compound W®, Little Remedies®, Boudreaux's Butt Paste®, Nix®, Debrox®, Gaviscon®, Hydralyte®, and Fess® [2]